← Back

Beta Bionics, Inc. Common Stock

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

Price · split & dividend adjusted
News & notes moving BBNX
Biotech & Genomic Medicine▲

Abbott wins FDA authorization for first dual glucose-ketone sensor

Abbott has received U.S. Food and Drug Administration authorization for its Libre Duo 10 Day system, the world's first dual glucose-ketone sensing technology for people with diabetes. The biowearable continuously monitors glucose and ketone levels, alerting users to rising ketones that can lead to diabetic ketoacidosis, a serious complication. Abbott plans to launch Libre Duo 10 Day in the United States later this year, with compatibility expected with Beta Bionics' iLet and Sequel Med Tech's twiist automated insulin delivery systems by the end of 2026 and with Insulet and Tandem devices in 2027. The system received De Novo authorization after securing breakthrough device designation from the FDA and is intended for people with diabetes ages 2 and older, offering up to 10 days of wear.
ABT ▲BBNX ▲PODD
Biotech & Genomic Medicine ▲
PR Newswire·1dRead more ▾
BBNX▼

Beta Bionics Fair Value Estimate Cut to $19.80 Amid Medtech Valuation Reset

The fair value estimate for Beta Bionics has been lowered from US$31.30 to US$19.80 per share, bringing it closer to analyst price targets that range from US$13 to US$22. The revision reflects updated assumptions including a reduction in long-term revenue growth from 38.41% to 35.78%, a lower projected net profit margin from 12.91% to 11.76%, and a smaller assumed future P/E multiple from 59.43x to 36.27x, while the discount rate moved from 7.67% to 7.38%. Analyst commentary highlights a balance between optimism around the iLet device and the planned Mint launch by the end of Q2 2027, and caution tied to broader medtech valuation resets and sector headwinds. Truist raised its target to US$22, Goldman Sachs to US$19, and BofA to US$13, though BofA had earlier cut its target from US$23 to US$11 citing a new reality of medtech valuations.
BBNX ▼
Simply Wall St·32dRead more ▾
BBNX▼

Johnson Fistel Investigates Beta Bionics Over Potential Securities Law Violations

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of Beta Bionics investors. The investigation concerns whether Beta Bionics or certain executive officers made false or misleading statements or failed to disclose material information about the company's growth trends, new patient starts, business outlook, and related operating metrics. On January 8, 2026, Beta Bionics announced preliminary unaudited fourth-quarter 2025 results, expecting at least 5,581 new patient starts, representing year-over-year growth of at least 36%. Despite the growth, the results fell below analyst expectations and reflected a significant deceleration from the prior quarter's 68% year-over-year growth in new patient starts. Investors who purchased Beta Bionics securities and suffered losses are encouraged to contact Johnson Fistel to discuss their legal rights.
BBNX ▼
GlobeNewswire·58dRead more ▾
© 2026 MarketDXAsset